Despite anecdotal reports to the contrary, a large observational study concludes that TNF inhibitors, compared with non-TNF biological or targeted synthetic DMARDs, do not cause higher rates of death or respiratory hospitalization in patients with RA-ILD.
The ARP & the Rheumatology Research Foundation are key partners in advancing rheumatology. Learn how they support care, training & research on their anniversaries.
Pediatric rheumatologic diseases are characterized by high rates of anxiety & depression known to impact health-related outcomes. CARRA and the ACR developed guidance statements to assess & manage mental health concerns for youths in pediatric rheumatology practice.
The 2026 Community Practice Innovation Award supports projects that enhance care delivery, improve outcomes and address real-world challenges in rheumatology.
In a powerful op-ed published by Fierce Healthcare, rheumatologists Amanda Myers, MD, and Rebecca Shepherd, MD, MBA—both volunteer advocates with the ACR—highlighted the critical role of the Centers for Medicare & Medicaid Services (CMS) in improving access to life-changing medications for patients with autoimmune and rheumatic diseases. Many patients with chronic conditions, such as rheumatoid…
If physicians and other healthcare workers are not exempted from the $100,000 fee, the rheumatology workforce may be negatively affected, possibly increasing pressure on existing providers and extending patient wait times.